HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masataka Sata Selected Research

Anticoagulants

7/2022Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism.
7/2020Association between Sarcopenia/Lower Muscle Mass and Short-Term Regression of Deep Vein Thrombosis Using Direct Oral Anticoagulants.
1/2019Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
1/2018Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
10/2015Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
6/2013Two cases of acute myocardial infarction during combined chemotherapy in young patients with testicular cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masataka Sata Research Topics

Disease

50Atherosclerosis
11/2023 - 12/2003
43Inflammation (Inflammations)
01/2023 - 06/2003
26Ischemia
01/2018 - 07/2002
22Coronary Artery Disease (Coronary Atherosclerosis)
11/2023 - 01/2005
21Heart Failure
01/2024 - 05/2003
21Hypertension (High Blood Pressure)
10/2023 - 06/2010
19Type 2 Diabetes Mellitus (MODY)
02/2024 - 01/2013
18Neoplasms (Cancer)
12/2023 - 10/2002
16Cardiovascular Diseases (Cardiovascular Disease)
11/2023 - 12/2010
16Neointima
12/2020 - 10/2002
15Insulin Resistance
09/2022 - 02/2010
15Hyperplasia
02/2014 - 08/2002
13Obesity
07/2022 - 04/2004
13Atherosclerotic Plaque (Atheroma)
11/2019 - 01/2008
13Vascular Remodeling
04/2013 - 04/2002
11Myocardial Infarction
01/2019 - 05/2004
10Thrombosis (Thrombus)
05/2024 - 06/2009
10Body Weight (Weight, Body)
11/2023 - 07/2004
10Diabetes Mellitus
01/2023 - 01/2011
10Fibrosis (Cirrhosis)
01/2021 - 10/2002
10Vascular System Injuries
02/2018 - 08/2002
7Atrial Fibrillation
03/2023 - 04/2010
7Myocardial Ischemia (Ischemic Heart Diseases)
01/2022 - 10/2002
7Carotid Artery Diseases
01/2020 - 04/2009
7Acute Coronary Syndrome
03/2019 - 08/2014
6Dyslipidemias (Dyslipidemia)
01/2022 - 01/2011
6Arteriosclerosis
01/2016 - 10/2004
5Rupture
05/2024 - 09/2011
5Hyperuricemia
07/2023 - 07/2011
5Pulmonary Arterial Hypertension
11/2015 - 01/2007
5Vascular Diseases (Vascular Disease)
02/2014 - 09/2003
4Aneurysm (Aneurysms)
05/2024 - 01/2011
4Proteinuria
03/2024 - 01/2004
4Bites and Stings (Sting)
11/2023 - 11/2021
4Venous Thromboembolism
07/2022 - 01/2018
4Hyperlipidemias (Hyperlipidemia)
03/2022 - 01/2011
4Cardiomyopathies (Cardiomyopathy)
01/2022 - 12/2009
4Left Ventricular Dysfunction
01/2021 - 12/2009
4Stroke (Strokes)
08/2017 - 12/2007
4Hypercholesterolemia
06/2017 - 08/2002
4Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2016 - 02/2010
4Essential Hypertension
01/2015 - 01/2009

Drug/Important Bio-Agent (IBA)

23LipidsIBA
11/2023 - 12/2009
19ApolipoproteinsIBA
11/2023 - 08/2002
18Apolipoproteins E (ApoE)IBA
11/2021 - 07/2005
18Angiotensin IIIBA
01/2021 - 10/2002
16Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023 - 06/2004
15Biomarkers (Surrogate Marker)IBA
01/2021 - 10/2009
13Proteins (Proteins, Gene)FDA Link
12/2015 - 12/2005
10Glucose (Dextrose)FDA LinkGeneric
01/2023 - 01/2013
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2013 - 05/2004
9DNA (Deoxyribonucleic Acid)IBA
11/2023 - 05/2004
8Eicosapentaenoic AcidIBA
03/2019 - 04/2008
7Sodium-Glucose Transporter 2 InhibitorsIBA
02/2024 - 01/2016
7CanagliflozinIBA
12/2022 - 04/2016
7Docosahexaenoic AcidsIBA
03/2019 - 12/2014
7Nitric Oxide (Nitrogen Monoxide)FDA Link
07/2013 - 04/2008
6Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
11/2023 - 05/2004
6Triglycerides (Triacylglycerol)IBA
11/2023 - 06/2011
6LDL CholesterolIBA
11/2023 - 02/2010
6Uric Acid (Urate)IBA
07/2023 - 07/2011
6CytokinesIBA
01/2023 - 08/2009
6SodiumIBA
01/2023 - 07/2016
6AnticoagulantsIBA
07/2022 - 06/2013
6CollagenIBA
10/2018 - 08/2004
6AdipokinesIBA
01/2018 - 08/2010
5InterferonsIBA
11/2023 - 05/2015
5Blood Glucose (Blood Sugar)IBA
11/2023 - 04/2016
5Brain Natriuretic Peptide (Natrecor)FDA Link
09/2023 - 12/2014
5Insulin (Novolin)FDA Link
01/2023 - 09/2013
5RivaroxabanIBA
07/2022 - 10/2015
5oxidized low density lipoproteinIBA
01/2022 - 02/2010
5LigandsIBA
01/2022 - 12/2005
5Factor Xa (Coagulation Factor Xa)IBA
01/2021 - 10/2015
5CholesterolIBA
01/2019 - 12/2007
5Telmisartan (Micardis)FDA Link
01/2014 - 01/2009
5Type 1 Angiotensin ReceptorIBA
12/2010 - 01/2005
4ipragliflozinIBA
02/2024 - 01/2016
4cyclic guanosine monophosphate-adenosine monophosphateIBA
11/2023 - 11/2021
4Messenger RNA (mRNA)IBA
01/2022 - 04/2005
4HDL CholesterolIBA
12/2021 - 05/2013
4Dipeptidyl-Peptidase IV InhibitorsIBA
11/2019 - 08/2015
4Toll-Like Receptor 9IBA
01/2019 - 12/2013
4Toll-Like Receptors (Toll-Like Receptor)IBA
01/2019 - 03/2011
4ThrombinFDA Link
01/2018 - 06/2007
4Ezetimibe (Zetia)FDA Link
01/2018 - 02/2010
4Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
10/2017 - 12/2014
4CreatinineIBA
01/2017 - 01/2004
4AdiponectinIBA
01/2017 - 10/2002
4HDL LipoproteinsIBA
10/2015 - 04/2007
4erucylphosphocholineIBA
09/2015 - 08/2009
4AldosteroneIBA
08/2014 - 04/2005
4Angiotensin II Type 1 Receptor BlockersIBA
01/2014 - 01/2005
4ONO 1301IBA
01/2013 - 07/2009

Therapy/Procedure

38Therapeutics
05/2024 - 04/2002
9Stents
03/2019 - 02/2005
8Transplantation
10/2018 - 08/2003
6Bone Marrow Transplantation (Transplantation, Bone Marrow)
12/2015 - 07/2005
5Percutaneous Coronary Intervention
11/2021 - 10/2009
4Cardiac Rehabilitation
10/2018 - 01/2014